Table 4.
Comparison of the performance of the models.
| Comparison | DeLong’s test* (p-value) in the testing cohort | DeLong’s test* (p-value) training cohorts |
|---|---|---|
| BPGT vs. MPGT | ||
| Clinical model vs. radiomics model | 0.404 | 0.103 |
| Clinical model vs. radiomics nomogram | 0.041 | 0.010 |
| Radiomics model vs. radiomics nomogram | 0.406 | 0.172 |
| PA vs. MPGT | ||
| Clinical model vs. radiomics model | 0.163 | 0.009 |
| Clinical model vs. radiomics nomogram | 0.048 | 0.013 |
| Radiomics model vs. radiomics nomogram | 0.434 | 0.100 |
| WT vs. MPGT | ||
| Clinical model vs. radiomics model | 0.359 | 0.046 |
| Clinical model vs. radiomics nomogram | 0.016 | 0.013 |
| Radiomics model vs. radiomics nomogram | 0.603 | 0.616 |
| PA vs. WT | ||
| Clinical model vs. radiomics model | 0.034 | 0.001 |
| Clinical model vs. radiomics nomogram | 0.006 | 0.000 |
| Radiomics model vs. radiomics nomogram | 0.395 | 0.519 |
p-value < 0.05 indicated a statistically significant difference. *Test for the comparison of the difference of AUC; Vs, versus; PA, pleomorphic adenomas; WT, Warthin tumor; BPGT, benign parotid gland tumor, MPGT, malignant parotid gland tumor.